Xponential Fitness, Inc. (XPOF) - Due Diligence

hourglass

Loading…

Preparing the latest DD data, styles and content.

47NeutralDD: Jun 18, 2026Analyst: 39

paidPrice at analysis date

USD 6.30 (18/06/2026)

domainMkt cap

pie_chartShares

candlestick_chart52W

trending_downShort interest

7.5%

MEDIUMNYSEConsumer Discretionary358 employeesFounded 2017

Verdict: Caution — Dislocation real, asymmetry weak (no hard floor)

SPECIAL_SIT screening identified XPOF on the back of an April 2026 strategic review with Jefferies, post-Kanen Wealth activist letter, plus a stock down ~43% from 52-week high $11.14. Independent DD concludes the asymmetry hypothesis only weakly holds: floor is SOFT (recurring franchise royalties, no net cash, negative tangible book of −$372M, net debt ~$500M). Take-out math at 8-9x adj. EBITDA on FY26 guide $100-110M yields equity ~$300-400M = ~$3.70-$4.90/Class A sh, BELOW current $6.30. Asymmetry ratio ~1.4x (base upside +30% vs downside −40% to recent low $3.83), below the 2.5x gate. Multiple unresolved litigation overhangs (FTC consent $17M, $22.75M franchisee settlement, ongoing securities class action) compress floor further. The strategic review IS a real binary catalyst, but it could close at par or trigger downside if no buyer emerges. Selection criteria were screening only; DD does not confirm a positive asymmetric setup.

📊 DIANALITICS RESEARCH INDEXCompany & Thesis Assessment Score /100 — updated 2026-06-18

Xponential Fitness, Inc. (XPOF)

Boutique Fitness Franchisor · NYSE · Irvine, CA

"Dislocation real, asymmetry weak: strategic review is the only credible re-rating path"

Strategic review −$372M equity Class action $120M+ royalties Soft floor

Fin. strength

/20 pts

EBITDA/FCF

/15 pts

Debt/leverage

/15 pts

Stage/business

/15 pts

Catalysts

/10 pts

Reg. risk

/8 pts

Risk/reward

/7 pts

Management

/5 pts

Sector/macro

/3 pts

Compliance

/2 pts

💡 Fair Value Estimate — EV/EBITDA on FY26E adj. EBITDA midpoint, M&A cross-check

Fair value base case

USD 6.80

Range: USD 3.83-USD 10.5

Price at analysis date: USD 6.30 (18/06/2026)

Base upside/downside: +8%

Methodology: Primary method EV/EBITDA bottoms-up on FY26E adj. EBITDA $105M × 9.0x derived multiple (peer median ~14x − 35% haircut for leverage, litigation, decel SSS, governance issues). Cross-check via M&A take-out math at 11-12x = $9-$10.50/sh in bull case (35% probability gives weighted contribution to base FV). Implied multiple of $6.80 FV = 10.1x EBITDA (~+12% vs nominal 9x, within ±20% but justified ONLY by take-out optionality). Asymmetry-gate test (under ASIM mode): floor downside −40% to $3.83 (52W low / pre-strategic-review level), upside +50% to bull $9.50 → ratio = 1.25x, FAILS 2.5x gate. The screening dislocation is real but the asymmetry hypothesis does NOT hold under independent DD. ⚠️ Not investment advice.

Component	Assumption	USD/share
Core franchise EV (operating)	FY26E adj. EBITDA $105M × 9.0x EV/EBITDA = $945M EV / 82M fully diluted (Class A 49M + LLC units ~33M)	+11.52
Net debt	Long-term debt $523.7M − cash $21.5M = $502.2M / 82M sh	−6.13
FTC + franchisee settlement NPV	$17M FTC + $22.75M franchisee = $39.75M nominal × 0.85 NPV factor = $33.8M / 82M sh	−0.41
Securities class action reserve	$30M expected liability (mid-range historical settlements for similar fact patterns) × 0.7 prob / 82M sh	−0.26
Tax Receivable Agreement (TRA) overhang	~$160M TRA obligation × 50% NPV haircut (long timing) / 82M sh	−0.98
Strategic review option value	Take-out probability 35% × $1.50/sh premium over standalone	+0.53
FV base case	Sum: 11.52 − 6.13 − 0.41 − 0.26 − 0.98 + 0.53	≈ $4.27 ⚠️ vs $6.30 mkt = −32%

Bull

$9.50–$10.50

Probability: 20%

Strategic review yields PE/strategic take-out at 11-12x EBITDA = $1.15-1.26B EV → ~$7.50-$9.30 equity/sh + 15-20% control premium = $9-$10.50. Requires real bidder by Q4 2026.

Base

USD 5.78-USD 7.82

Probability: 45%

Strategic review concludes "standalone" or no acceptable bid. SSS stabilizes at −2% to flat, FY26 EBITDA $100M delivered. Multiple stays 7-9x. Stock drifts in current range; analyst consensus $7.21 anchors upside.

Bear

$3.50–$4.50

Probability: 35%

No deal; Q2-Q3 SSS continues negative; securities class action settles material amount; debt refinancing pressure; multiple compresses to 5-6x. Stock revisits 52W low $3.83 or below. Floor only as strong as forward royalty stream.

Methodology: Methodology: Primary method EV/EBITDA bottoms-up on FY26E adj. EBITDA $105M × 9.0x derived multiple (peer median ~14x − 35% haircut for leverage, litigation, decel SSS, governance issues). Cross-check via M&A take-out math at 11-12x = $9-$10.50/sh in bull case (35% probability gives weighted contribution to base FV). Implied multiple of $6.80 FV = 10.1x EBITDA (~+12% vs nominal 9x, within ±20% but justified ONLY by take-out optionality). Asymmetry-gate test (under ASIM mode): floor downside −40% to $3.83 (52W low / pre-strategic-review level), upside +50% to bull $9.50 → ratio = 1.25x, FAILS 2.5x gate. The screening dislocation is real but the asymmetry hypothesis does NOT hold under independent DD. ⚠️ Not investment advice. Not investment advice.

warning

⚠️ Multiple material risk overhangs — read before any positioning

(1) Securities class action investigations active (Schall, Rosen, Kessler Topaz, Bragar Eagel) — stock dropped 47% on Feb 27 2026 on related disclosures. (2) FTC stipulated consent agreement Feb 2026 — $17M payable over 12 months. (3) $22.75M franchisee class settlement to 500+ current/former franchisees (35-month payout). (4) Negative stockholders' equity of −$372M; net debt ~$500M against just $21.5M cash + $9.3M restricted. (5) Q1 2026 EBITDA −25% YoY, SSS −6.2%. The strategic-alternatives review is the only credible re-rating catalyst, but the floor under the stock is not hard.

⚠️ Methodology note: Profile classified as SPECIAL_SIT under ASIMMETRIA mode (strategic review + activist pressure + heavy drawdown). Per the screening dictum, classification is a SELECTION criterion, NOT a conclusion. Fair value is derived bottom-up from FY26E adj. EBITDA × peer-derived EV/EBITDA multiple, with cross-check vs M&A take-out math. Scenario weights: bull 20% / base 45% / bear 35% — slight bear tilt because the supposed floor is contractual royalty stream rather than net cash or tangible book, and litigation outcomes are open-ended.

📊 Capital Structure · Short Interest · Buyback & Dilution

🟠 Short Interest

~7.5%

3.68M shares short on float (latest StockAnalysis Apr 2026); some sources report up to 18.9% on Class A float ex-LLC units. Days to cover ~5. Bear positioning ahead of strategic-review outcome and Q2 earnings.

🟢 Share dilution (1Y)

+1.6%

Class A: 48.4M → 49.18M (modest RSU vesting). LLC units ~33M unchanged. Recent 219K-RSU grant to new President (D. Porto Parra) vests over 3 years. No equity raise in 12M.

🔴 Buyback

No buyback active. Capital priority is FTC settlement payments ($17M over 12M) + franchisee settlement ($22.75M over 35M) + debt service. No dividend.

Short Interest — context

XPOF — 7.5% (Apr 2026 SA)

7.5%

XPOF — 18.9% (alt. float basis)

18.9%

Insider activity (last 12M): All insider transactions Form 4 are RSU grants or tax-withholding sales (Code F, non-elective). Notable: President Porto Parra appointed May 18 with 219,905-share RSU grant; COO Weiderhoft separated May 13; CFO Meloun had 29,738 sh withheld at $5.53 for taxes. NO open-market insider buys >$500K, NO discretionary sales >$500K in trailing 12M. Strategic review was triggered by activist letter from Kanen Wealth Management (4% holder) on April 1, 2026.

$Financial analysis — FY26E

FY26 Revenue guide

$260-270M

~−16% vs FY25 $314.9M

FY26 Adj. EBITDA guide

$100-110M

39.6% margin midpoint

Cash (Q1 FY26)

$21.5M

+$9.3M restricted

Net debt / EBITDA

$502M / 4.8x

High leverage

Item	FY23A	FY24A	FY25A	FY26E	Guidance FY26
Total revenue ($M)	286.6	320.4	314.9	~265	$260-270M
Adj. EBITDA ($M)	105.0	120.5	~110	~105	$100-110M
Adj. EBITDA margin	36.6%	37.6%	~35%	~39.6%	Margin up on mix
Net loss ($M)	−21	−73	−51.1	~−48	Loss persists
NA same-store sales	+10%	+3%	−2%	−6%	Re-acceleration H2?
Net debt ($M)	~430	~470	~495	~502	Settlement drag

FY26 revenue guide was cut 16% vs prior reference at Q4 2025 reporting. FY25 actuals reflect divestiture of CycleBar/Row House non-core brands. NA same-store sales Q1 2026 was −6.2%, the worst quarter in 4 years.

Quarterly dynamics — last 5 quarters
Metric	Q1 FY25	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26
Revenue ($M)	76.4	80.2	79.1	79.2	60.7
Adj. EBITDA ($M)	27.3	30.1	29.5	22.0	20.4
NA SSS %	5.2	2.8	−1.0	−4.2	−6.2
End-of-period cash ($M)	32.4	29.8	28.5	23.1	21.5

Financial position and sustainability

Cash / Market cap

~7%

Royalty stream / EV

~14%

Net debt / FY26E EBITDA

4.8x

SSS trend (worsening)

−6.2%

account_tree

Business model — Boutique fitness franchisor (asset-light, royalty-driven)

Multi-brand boutique fitness platform with contracted-but-deferred growth

Xponential is the largest franchisor of boutique health/wellness brands globally, with 10 brands (Club Pilates, Pure Barre, StretchLab, YogaSix, CycleBar, AKT, BFT, Rumble, STRIDE, Lindora). As of Q1 2026: 3,200+ studios open globally + 780 NA contracted licenses + 750 international master franchise obligations = 4,700+ studios contractually visible. Revenue is fundamentally asset-light: franchise royalties (~6.5% of system sales), franchise fees, equipment, B2B. System-wide NA sales Q1 2026 $437M (+2% YoY). The reason the stock is dislocated despite an attractive model: same-store sales are negative (−6.2% Q1), customer-acquisition costs have spiked on digital ad inflation, and the company carries $500M+ debt while burning cash to settle FTC and franchisee disputes. Net result: high-quality asset wrapped in a stressed capital structure.

Franchise revenue (royalties + fees) ~$170M FY26E (~64% rev) 🔴 declining Royalty-based recurring revenue tied to system-wide sales × 6.5%. Q1 2026 −$2.7M YoY on SSS compression + 2025 brand divestitures. Highest-margin segment (GM >90%). The "asset" that any buyer would value. Equipment & merchandise ~$55M FY26E (~21% rev) 🟡 stable Pass-through equipment sales to franchisees opening new studios. Tied to license openings (28 sold globally Q1). Lower margin (~15-20%) but counter-cyclical to SSS as new units open even when comparable units weaken. B2B + international ramp ~$40M FY26E (~15% rev) 🟢 ramping Riser Fitness multi-unit deal (April 2026, largest in company history). 750 intl master franchise obligations form long-tail growth. New President Porto Parra has consumer-brand pedigree relevant to scaling intl exec.

gavel

Legal, regulatory and risk analysis

Securities class action investigations (active)

Critical

Schall, Rosen, Kessler Topaz, Bragar Eagel investigating securities fraud claims. Trigger event: Feb 27 2026 stock dropped 47% on FTC consent + franchisee settlement disclosures. Class period not finalized. Expected liability $20-50M range based on historical settlements for similar facts.

Net debt $502M on negative equity (−$372M)

Critical

Long-term debt $523.7M against $21.5M cash + $9.3M restricted. Net debt/FY26E EBITDA = 4.8x — covenant-relevant level. Management states 12-month liquidity adequate; debt refinancing window in 2027-2028 will be tested by SSS trajectory.

Same-store sales decline accelerating

High

NA SSS trend: +5.2% Q1'25 → −6.2% Q1'26. 13ppt swing in 4 quarters. Digital-marketing CAC inflation + GLP-1 demand-side disruption (less foot-traffic in fitness) are structural headwinds. Royalty floor erodes 1:1 with SSS.

FTC consent decree + franchisee settlement

High

$17M FTC payment over 12 months (signed Feb 2026) + $22.75M franchisee class settlement (500+ ex-franchisees, 35-month payout). Total ~$40M cash drain. Stipulated consent may impose ongoing compliance constraints on franchise sales process.

Tax Receivable Agreement overhang

Moderate

Up-C structure includes a TRA payable to legacy LLC unit holders for tax benefits realized. Estimated ~$160M obligation NPV. Acquirer would need to assume or trigger this — affects M&A deal economics negatively.

Strategic review with Jefferies (Apr 2026)

Positive Catalyst

Independent directors initiated formal review April 6 2026 after Kanen letter (April 1). Jefferies engaged as advisor. Could yield sale to PE (Roark Capital, Bain Capital are franchise specialists), strategic (LTH? PLNT?), or partial divestiture. Dated catalyst (typically 6-9 months from initiation).

Asset-light franchise model resilience

Positive

780 NA + 750 intl licenses contractually obligated to open form a 4-5 year unit pipeline. Each new unit adds to royalty base even if SSS stays negative. Brand portfolio (esp. Club Pilates) retains acquisition-relevant equity.

Management churn (COO out, new President)

Moderate

COO Weiderhoft departed May 13 2026; new President Porto Parra appointed May 18 2026. Transition during strategic review introduces execution risk but also may signal preparation for a sale (PE-friendly leadership reset).

public

SWOT analysis

Strengths

+Asset-light franchise model with 90%+ GM royalty stream and 4,700+ visible studios in pipeline
+Largest boutique-fitness franchisor in NA; Club Pilates is category-leading brand
+Recurring revenue base provides predictable cash flow even in weak SSS quarters
+Strategic review with top-tier advisor (Jefferies) creates real M&A optionality

Weaknesses

−Negative stockholders' equity (−$372M); net debt 4.8x EBITDA; covenant cushion thin
−SSS down 6.2% in Q1 2026 — 13ppt deceleration in 4 quarters
−$40M+ litigation/settlement cash drain over next 1-3 years (FTC + franchisee)
−Tax Receivable Agreement (~$160M) complicates M&A economics

Opportunities

→Take-out by PE (Roark, Bain) at 11-12x EBITDA = $9-10.50/sh equity
→International ramp (750 master franchise obligations) is largely un-priced
→Multiple re-rating if SSS inflects positive in H2 2026
→Lindora and BFT brands (post-acquisition) could ramp into meaningful contributors

Threats

!GLP-1 demand shock to in-person fitness; CAC inflation digital marketing
!Securities class action settlement material; SEC investigation closed but reputational damage lingers
!Strategic review concludes "standalone" → no buyer emerges → multiple compression toward DNUT-style distressed range
!Debt refi window 2027-2028 in stressed credit environment

Bull thesis (20%)

PE take-out (Roark, Bain) at 11-12x EBITDA

Equity value $9-10.50/sh post premium

Strategic review concludes by Q4 2026

SSS inflects positive H2 on Porto Parra plan

Base scenario (45%)

Strategic review concludes "standalone"

SSS stabilizes at −2% to flat by Q4

FY26 EBITDA $100-110M delivered

Stock drifts in $5.50-$7.50 range

Bear scenario (35%)

No deal; class action settles material

SSS stays −5% to −8%; debt covenant pressure

Multiple compresses to 5-6x EBITDA

Stock revisits 52W low $3.83 or below

{ "verdict_label": {"it": "Cautela — dislocazione reale, asimmetria debole", "en": "Caution — Dislocation real, asymmetry weak"}, "verdict_text": {"it": "XPOF è in strategic review con Jefferies dopo lettera dell'attivista Kanen. La quotazione (~$6.30) è giù del 43% dai massimi, ma manca un floor duro: equity negativo (−$372M), debito netto $502M, litigation aperta ($17M FTC + $22.75M franchisee + class action securities). Bottom-up EV/EBITDA dà FV $4.27 (sotto il prezzo); il blended FV $6.80 incorpora 35% di probabilità take-out. Ratio asimmetria ~1.4x, sotto la soglia 2.5x.", "en": "XPOF is in strategic review with Jefferies after activist Kanen letter. Stock (~$6.30) is 43% off 52-week high but lacks a hard floor: negative equity (−$372M), $502M net debt, open litigation ($17M FTC + $22.75M franchisee + securities class action). Bottoms-up EV/EBITDA gives FV $4.27 (below current); blended FV $6.80 includes 35% take-out probability. Asymmetry ratio ~1.4x, below 2.5x gate."}, "bull_points": [ {"it": "Strategic review con Jefferies = catalyst datato (PE Roark/Bain candidati)", "en": "Strategic review with Jefferies = dated catalyst (Roark/Bain logical PE bidders)"}, {"it": "Modello franchise asset-light: 4,700+ studios contratti, royalty ~$170M, GM>90%", "en": "Asset-light franchise model: 4,700+ contracted studios, ~$170M royalties, GM>90%"}, {"it": "Take-out a 11-12x EBITDA porta equity a $9-10.50/sh (+50% vs spot)", "en": "Take-out at 11-12x EBITDA implies $9-10.50/sh equity (+50% vs spot)"} ], "bear_points": [ {"it": "Equity negativo −$372M, debito netto 4.8x EBITDA: nessun floor duro", "en": "Negative equity −$372M, 4.8x net leverage: no hard floor"}, {"it": "SSS in deterioramento (+5.2% Q1'25 → −6.2% Q1'26), CAC marketing in salita", "en": "SSS deteriorating (+5.2% Q1'25 → −6.2% Q1'26), digital CAC inflation"}, {"it": "Litigation $40M+ cash drain + class action securities aperta", "en": "$40M+ litigation cash drain + active securities class action"} ], "risks": [ {"it": "Strategic review chiude 'standalone' senza buyer: ritorno a $3.83-$4.50", "en": "Strategic review concludes 'standalone' with no buyer: revisit $3.83-$4.50"}, {"it": "Class action securities provision >$30M intacca FY26 EBITDA", "en": "Securities class action provision >$30M hits FY26 EBITDA"}, {"it": "Covenant covenant 5x leverage approaching su FY26 actuals", "en": "5x leverage covenant approaching on FY26 actuals"} ] }

Sources & Disclaimer

Sources: XPOF Q1 2026 10-Q (filed May 8, 2026, SEC EDGAR); Q1 2026 earnings release (BusinessWire May 6, 2026); strategic alternatives review announcement (BusinessWire April 6, 2026); FTC consent stipulation (Form 8-K, Feb 26, 2026); franchisee class settlement disclosure; analyst reports Northland (upgraded to Outperform $8 PT, May 2026), Roth ($7 PT), UBS ($7 PT), Lake Street ($6 PT), Raymond James (downgrade to Market Perform). Stock price: $6.30 (close 2026-06-17, T-1); cross-checked vs $5.72 (stockanalysis.com snapshot June 9), $6.82 (Yahoo Finance June 15). Peer multiples from stockanalysis.com industry comp tables. Market data — last verified close 2026-06-17. ⚠️ Not investment advice. Independent analytical report based on public disclosures; no portfolio position recommended.